The momentum is snowballing, and 2021 will be even bigger and better for psychedelics. After a year like 2020, it’s hard to know what the next year will bring. But we’ve got a feeling it’s going to be quite the ride for psychedelics.
Similar Posts
Interview with Rick Doblin, Executive Director and Founder of MAPS
In this episode, Rick and James Hallifax discuss MAPS’ work treating PTSD with MDMA, sending the Soviets Psychedelics, and what the future holds.
Interview With Dr. Steven Mandel
In this episode of the Psychedelic Spotlight podcast, we have the distinct privilege of speaking with one of the foremost experts in ketamine-assisted therapy, Dr. Steven L. Mandel, Founder and President of Ketamine Clinics Los Angeles.
Incorporating Psilocybin Mushrooms in Your Professional Life with Edward Crowe
In this episode, we speak with Edward Crowe about how his relationship with psilocybin mushrooms helps him navigate his personal and professional life.
![BIG NEWS on MindMed’s Clinical Trials [ Important MMED/MMEDF UPDATES You Need to Know ]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-37-600x338.jpeg)
BIG NEWS on MindMed’s Clinical Trials [ Important MMED/MMEDF UPDATES You Need to Know ]
Hello Psychedelic Investors! Today, we will focus on MindMed’s 2021 Investors Deck and Project Lucy & Project Layla’s clinical trials updates.
MindMed, ticker symbol MMED on the Canadian NEO Stock exchange, and MMEDF on the American OTC Market has updated their 2021 Investors Deck (TWICE) in this year. As a fellow MindMed geek, I did my due diligence to compare the information on both decks and there’s a few clinical trial changes and a few other updates I found important to discuss.
In this episode, we will discuss:
Timecodes
0:00 – Intro
3:02 – MindMed’s Project Lucy Updates
6:27 – MMED’s18-MC And Microdosing Updates
9:00 – LSD to treat Suicide Headaches
11:04 – Phase 1 Updates
14:06 – Stats Updates
15:32 – MindMed Stock Speculation Zone
Important to mention that after we shot this video, MindMed did answer our inquiry about the removed readout with “Hello – Sorry for the delay. We plan on filing the IND for Project Lucy in Q3 of 2021.”
I’m not sure if that means that there will be a readout in Q3 as well…
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video by Pressmaster from Pexels
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMEDF #MindmedStock
Two Psychedelic Companies Run Out of Money: Will it Cause a Domino Effect? | Plus MindMed Stock News
Two Psychedelic Medicines Companies Run out of Money. What is next for psychedelic stocks? Plus a MindMed Stock Update( MMED / MMED)
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC
A second domino is falling in the world of psychedelic stock investing.
Last week, Psychedelic Spotlight reported that Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) was halting its psychedelic medicines research, following a “strategic review” undertaken by the company.
In short, they ran out of money.
As I have stated repeatedly, running a psychedelic research company is ridiculously expensive, and many smaller companies with low market caps and little money in the bank will find it hard to survive in a market context of low stock prices.
At the time, I speculated that “we shouldn’t be surprised if this is just the first domino,” and unfortunately, it didn’t take much time for the prophecy to be realized.
On March 19th, psychedelics company Core One Labs (CSE: COOL) (OTC: CLABF) announced that they are “working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies.”
Or, in other words, they too have run out of money and are looking for a financial savior.
This wasn’t particularly surprising. Taking a cursory look at their financials, we can see the dire position the company is in. As of the end of September, the company had $587,000 CAD in the bank, and they were spending more than $5 million per quarter. With a market cap of around $32 million, Core One would have to dilute their stock by more than 15% each quarter to keep spending at the same levels. This, obviously, is an unsustainable proposition.
So, with two psychedelic medicine companies essentially announcing that they no longer have the financial wherewithal to continue operations, does it mean that the end of psychedelic stocks is near?
No, it most certainly does not.
To start, we need to understand that the psychedelics companies that are beginning to falter are the ones who were already in bad financial shape. There are many companies that have strong financials, and do not need to worry about refinancing any time soon. A short and non-exhaustive list of these companies include: atai Life Sciences (Nasdaq: ATAI); MindMed (Nasdaq: MNMD) (NEO: MMED); and Small Pharma (TSXV: DMT) (OTCQB: DMTTF). Even if — and I judge this to be likely — more small-cap psychedelics companies follow Mind Cure and Core One Labs’ lead, the more financially stable companies won’t be affected.
Sources:
PsychedelicSpotlight.com article: https://psychedelicspotlight.com/another-psychedelics-company-core-one-labs-is-crashing-is-industry-in-trouble/
MindCure Press release: https://www.newswire.ca/news-releases/mindcure-provides-update-on-strategic-review-891232484.html
Core One Labs Press Release: https://www.globenewswire.com/news-release/2022/03/19/2406329/0/en/Core-One-Labs-to-Investigate-Soliciting-Investment-and-Potential-Takeover-Opportunities.html
Core One Labs $100/ gram psilocybin: https://www.globenewswire.com/news-release/2022/02/23/2390219/0/en/Vancouver-discovery-will-make-Magic-Mushroom-mental-health-care-cheaper.html
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#PsychedelicStocks #Psychedelics #Investing